Electrome.io × BIEL Is Far More Advantageous Than Any Partnership With SoftPulse/ENDV
In the electrotherapeutics space, not all hardware partners are created equal. For Electrome.io, the choice between BIEL and SoftPulse/ENDV isn’t a strategic debate — it’s a structural mismatch versus a structural multiplier.
BIEL is the only partner that offers FDA‑cleared, mass‑market hardware, global scale, and a massive installed base.
SoftPulse/ENDV simply cannot match these fundamentals.
A collaboration with BIEL doesn’t just create value — it creates a category‑defining platform that SoftPulse/ENDV is NOT positioned to enable.
1. BIEL Is the Only Partner With FDA‑Cleared, Mass‑Market Hardware
This is the single biggest differentiator.
BIEL
Multiple FDA‑cleared PEMF devices
Proven safety and efficacy
Millions of units sold globally
Active in both consumer and clinical markets
SoftPulse / ENDV
Limited or no FDA‑cleared consumer devices
Early‑stage or niche clinical products
Minimal regulatory traction
Small installed base
Why it matters:
Electrome.io can integrate with BIEL immediately — no waiting years for approvals, trials, or regulatory risk.
This accelerates:
Time to market
Investor confidence
Revenue generation
Clinical adoption
SoftPulse/ENDV cannot offer this.
2. BIEL Has Scalable Manufacturing and Global Distribution
Electrome.io needs a hardware partner that can scale. Only BIEL fits that requirement.
BIEL
Mature supply chain
Low‑cost, high‑volume manufacturing
Retail + clinical distribution channels
Proven global scalability
SoftPulse / ENDV
Limited production capacity
Higher device costs
Minimal distribution
Why it matters:
Electrome.io can focus on software, AI, and data — not factories, logistics, or supply chain headaches.
3. BIEL Unlocks the Largest Real‑World PEMF Dataset in the World
BIEL has sold millions of devices — none connected yet.
Electrome.io becomes the intelligence layer that unlocks:
Usage data
Pain‑reduction outcomes
Recovery metrics
Population‑level PEMF insights
SoftPulse/ENDV cannot match this scale. Their installed base is tiny.
Data is the moat.
Electrome.io + BIEL could create:
The world’s largest PEMF outcomes dataset
Predictive models for personalized therapy
Stronger reimbursement evidence
A defensible competitive advantage
4. BIEL’s Technology Is Simpler, Safer, and More Consumer‑Friendly
Electrome.io thrives when hardware is:
Safe
Wearable
Affordable
OTC‑cleared
Easy to integrate
BIEL checks every box.
SoftPulse/ENDV do not.
Their tech is:
Higher‑intensity
More clinical‑only
More complex to regulate
Less consumer‑friendly
BIEL’s platform is the only one ready for mass‑market digital therapeutics.
5. BIEL Enables a Better, More Scalable Business Model
With BIEL, Electrome.io can build:
A connected PEMF patch
A subscription‑based digital therapeutic
Athlete recovery platforms
Remote patient monitoring tools
Clinical dashboards
Because BIEL’s hardware is low‑cost and scalable, Electrome.io monetizes software, not expensive devices.
SoftPulse/ENDV hardware is too costly and too limited to support a subscription‑driven model.
6. BIEL Has Global Brand Recognition and Market Penetration
Even if BIEL isn’t a household name, its products are:
Sold worldwide
Used by millions
Backed by clinical studies
SoftPulse/ENDV simply do not have this footprint.
Electrome.io benefits from:
Instant credibility
A built‑in customer base
Faster adoption
Easier clinical partnerships
7. Electrome.io Becomes the “Brain” of a Proven Hardware Platform
With BIEL, Electrome.io can transform simple PEMF patches into:
Smart, adaptive therapeutics
Data‑driven recovery systems
AI‑optimized pain‑management tools
With SoftPulse/ENDV, Electrome.io would be:
Supporting niche, clinical‑only devices
Limited in scale
Slower to market
Less attractive to investors
The Strategic Case for BIEL — In One Line
Electrome.io + BIEL = the fastest, safest, most scalable path to becoming the intelligence layer of next‑generation electrotherapeutics.
SoftPulse/ENDV simply cannot offer:
FDA‑cleared hardware
A massive installed base
Scalable manufacturing
Global distribution
Low regulatory friction
A huge data opportunity
A consumer‑friendly platform
A viable subscription model
BIEL CAN!
In the electrotherapeutics space, not all hardware partners are created equal. For Electrome.io, the choice between BIEL and SoftPulse/ENDV isn’t a strategic debate — it’s a structural mismatch versus a structural multiplier.
BIEL is the only partner that offers FDA‑cleared, mass‑market hardware, global scale, and a massive installed base.
SoftPulse/ENDV simply cannot match these fundamentals.
A collaboration with BIEL doesn’t just create value — it creates a category‑defining platform that SoftPulse/ENDV is NOT positioned to enable.
1. BIEL Is the Only Partner With FDA‑Cleared, Mass‑Market Hardware
This is the single biggest differentiator.
BIEL
Multiple FDA‑cleared PEMF devices
Proven safety and efficacy
Millions of units sold globally
Active in both consumer and clinical markets
SoftPulse / ENDV
Limited or no FDA‑cleared consumer devices
Early‑stage or niche clinical products
Minimal regulatory traction
Small installed base
Why it matters:
Electrome.io can integrate with BIEL immediately — no waiting years for approvals, trials, or regulatory risk.
This accelerates:
Time to market
Investor confidence
Revenue generation
Clinical adoption
SoftPulse/ENDV cannot offer this.
2. BIEL Has Scalable Manufacturing and Global Distribution
Electrome.io needs a hardware partner that can scale. Only BIEL fits that requirement.
BIEL
Mature supply chain
Low‑cost, high‑volume manufacturing
Retail + clinical distribution channels
Proven global scalability
SoftPulse / ENDV
Limited production capacity
Higher device costs
Minimal distribution
Why it matters:
Electrome.io can focus on software, AI, and data — not factories, logistics, or supply chain headaches.
3. BIEL Unlocks the Largest Real‑World PEMF Dataset in the World
BIEL has sold millions of devices — none connected yet.
Electrome.io becomes the intelligence layer that unlocks:
Usage data
Pain‑reduction outcomes
Recovery metrics
Population‑level PEMF insights
SoftPulse/ENDV cannot match this scale. Their installed base is tiny.
Data is the moat.
Electrome.io + BIEL could create:
The world’s largest PEMF outcomes dataset
Predictive models for personalized therapy
Stronger reimbursement evidence
A defensible competitive advantage
4. BIEL’s Technology Is Simpler, Safer, and More Consumer‑Friendly
Electrome.io thrives when hardware is:
Safe
Wearable
Affordable
OTC‑cleared
Easy to integrate
BIEL checks every box.
SoftPulse/ENDV do not.
Their tech is:
Higher‑intensity
More clinical‑only
More complex to regulate
Less consumer‑friendly
BIEL’s platform is the only one ready for mass‑market digital therapeutics.
5. BIEL Enables a Better, More Scalable Business Model
With BIEL, Electrome.io can build:
A connected PEMF patch
A subscription‑based digital therapeutic
Athlete recovery platforms
Remote patient monitoring tools
Clinical dashboards
Because BIEL’s hardware is low‑cost and scalable, Electrome.io monetizes software, not expensive devices.
SoftPulse/ENDV hardware is too costly and too limited to support a subscription‑driven model.
6. BIEL Has Global Brand Recognition and Market Penetration
Even if BIEL isn’t a household name, its products are:
Sold worldwide
Used by millions
Backed by clinical studies
SoftPulse/ENDV simply do not have this footprint.
Electrome.io benefits from:
Instant credibility
A built‑in customer base
Faster adoption
Easier clinical partnerships
7. Electrome.io Becomes the “Brain” of a Proven Hardware Platform
With BIEL, Electrome.io can transform simple PEMF patches into:
Smart, adaptive therapeutics
Data‑driven recovery systems
AI‑optimized pain‑management tools
With SoftPulse/ENDV, Electrome.io would be:
Supporting niche, clinical‑only devices
Limited in scale
Slower to market
Less attractive to investors
The Strategic Case for BIEL — In One Line
Electrome.io + BIEL = the fastest, safest, most scalable path to becoming the intelligence layer of next‑generation electrotherapeutics.
SoftPulse/ENDV simply cannot offer:
FDA‑cleared hardware
A massive installed base
Scalable manufacturing
Global distribution
Low regulatory friction
A huge data opportunity
A consumer‑friendly platform
A viable subscription model
BIEL CAN!
3
